|
Video: What is a Stock Split?
|
|
Genprex is a clinical stage gene therapy company focusing on the development of gene-based therapies. Co.'s oncology platform utilizes its non-viral ONCOPREX Nanoparticle Delivery System. Co.'s primary oncology drug candidate, REQORSA Immunogene Therapy, is being developed in combination with cancer drugs to treat Non-Small Cell Lung Cancer and Small Cell Lung Cancer. The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. In diabetes, Co. has licensed from the University of Pittsburgh of the Commonwealth System of Higher Education multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes. According to our Genprex stock split history records, Genprex has had 1 split. | |
|
Genprex (GNPX) has 1 split in our Genprex stock split history database. The split for GNPX took place on February 02, 2024. This was a 1 for 40 reverse split, meaning for each 40 shares of GNPX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as Genprex conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Genprex stock split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Genprex shares, starting with a $10,000 purchase of GNPX, presented on a split-history-adjusted basis factoring in the complete Genprex stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/02/2018 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$180.00 |
|
End price/share: |
$2.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.82% |
|
Average Annual Total Return: |
-51.90% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$117.79 |
|
Years: |
6.07 |
|
|
|
Date |
Ratio |
02/02/2024 | 1 for 40 |
|
|